icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
ZS3ckweUvuCf70gc